The Series B funding round led by DigitalDx Ventures will support development and commercialization of more than 30 rapid diagnostic tests in NOWDx’s clinical research pipeline, including its First To Know Syphilis OTC test, currently under US FDA De Novo review, which provides at-home results in minutes.
NOWDiagnostics, Inc. aims to accelerate the development and commercialization of at-home diagnostic tests with $22.5m in series B funding, announced on 9 July.
The Springdale, AK-based company’s First To Know Syphilis OTC test is undergoing De Novo review by the US Food and...